Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

2.

A prostate cancer risk prediction algorithm could help target men at highest risk

3.

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

4.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

5.

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot